ArticleJournal of inflammation research2025
NRF2 Deficiency in Bladder Epithelial Cells Owing to Ubiquitination by N6-Methyladenosine-Modified TRIM21 Induces Oxidative Stress and Inflammation to Aggravate IC/BPS.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploration and experimental validation of oxidative stress-related diagnostic genes in interstitial cystitis based on transcriptomics.Translational andrology and urology · 2026Article
- Pathophysiology and multi-target prevention strategies for cyclophosphamide-induced bladder injury.iScience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) has become a pressing clinical issue due to its unclear etiology and severe, persistent pelvic pain. Despite extensive research, the pathogenesis of IC/BPS remains unresolved, and current treatments primarily target symptom relief rather than addressing underlying disease mechanisms. This study aimed to investigate the effects of nuclear factor erythroid 2-related factor 2 (NRF2) on IC/BPS and the potential molecular mechanisms. Methods: Bladder mucosal biopsies from IC/BPS patients were subjected to RT-qPCR and immunoblotting to quantify NRF2 mRNA/protein expression. In vivo modeling, WT and NRF2 gene knockout mice received intraperitoneal cyclophosphamide to induce cystitis. Bladder function was assessed via Void Spot Assays, and Urodynamic. In vitro validation, LPS-stimulated SV-HUC-1 cells were transduced with NRF2 knockdown or overexpression, and oxidative stress and inflammation levels were evaluated. Then, the molecular mechanism of NRF2 in IC/BPS was determined by conducting Western blot, mass spectrometry, co-immunoprecipitation, and RT-qPCR analyses. Results: This study identified markedly reduced expression of NRF2 in the lesional bladder mucosa of patients with IC/BPS. By employing NRF2 knockout mice and cellular models of bladder inflammation, the essential role of NRF2 in modulating oxidative stress and inflammation was underscored. Furthermore, tripartite motif-containing 21 (TRIM21) interacted with NRF2, promoting its degradation via ubiquitination in bladder epithelial cell lines, thus elucidating TRIM21's regulatory role in bladder inflammation. Additionally, N6-methyladenosine (M6A) modifications recognized by IGF2BP2 enhanced TRIM21 expression by stabilizing TRIM21 mRNA. Conclusion: This study positions the TRIM21-NRF2 axis as a key regulator of oxidative stress and inflammation in IC/BPS and suggests it as a promising therapeutic target for future IC/BPS interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.